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Introduction
The Hippo signaling pathway was originally discovered in 
Drosophila melanogaster and has recently emerged as a po-
tent regulator of cell proliferation and organ size (Badouel   
et al., 2009; Zhang et al., 2009b). Several components of the 
pathway act as tumor suppressors or as protooncogenes (Harvey 
and Tapon, 2007). Core components of the Hippo pathway 
include  the  upstream  activator  Merlin/Nf2  (Hamaratoglu   
et al., 2006), a gene that is mutated in tumors of nervous tissue 
(Trofatter et al., 1993; Ruttledge et al., 1994) and in renal cell 
carcinoma (Forbes et al., 2008; Morris and McClatchey, 2009; 
Dalgliesh et al., 2010), the Ser/Thr kinases MST1/2 (mam-
malian STE20 kinases 1 and 2) and Lats1/2 (large tumor sup-
pressor 1 and 2), together with their coactivators WW45 and 
Mob. In the active state, Lats1/2 phosphorylates the transcrip-
tional activators Yes-associated protein (YAP) and TAZ (transcrip-
tional  coactivator  with  PDZ-binding  domain).  This  results   
in their cytoplasmic retention by binding to 14-3-3 (Kango-
Singh and Singh, 2009), preventing TAZ- and YAP-dependent 
transcription, which is mediated predominantly by transcrip-
tion factors of the TEA domain (TEAD) family (Wang et al., 
2009).  Although  the  upstream  components  of  the  Hippo   
signaling cascade Nf2, Fat4, MST1/2, Lats1/2, WW45, and 
Mob1 all function as tumor suppressors (Fernandez-L and 
Kenney, 2010), YAP and TAZ are highly expressed in several 
cancers and are considered to be oncogenes because over-
expression of both TAZ and YAP results in enhanced prolifer-
ation and transformation of epithelial cells (Overholtzer et al., 
2006; Zender et al., 2006; Chan et al., 2008; Lei et al., 2008). 
TAZ and YAP seem to have both overlapping and distinct 
functions in development. YAP knockout mice display em-
bryonic  lethality  (Morin-Kensicki  et  al.,  2006),  whereas 
TAZ-null mice are viable but develop severe degenerative 
T
he  conserved  Hippo  signaling  pathway  regulates 
organ size in Drosophila melanogaster and mam-
mals and has an essential role in tumor suppres-
sion and the control of cell proliferation. Recent studies 
identified activators of Hippo signaling, but antagonists   
of the pathway have remained largely elusive. In this   
paper, we show that NPHP4, a known cilia-associated 
protein that is mutated in the severe degenerative renal 
disease nephronophthisis, acts as a potent negative regula-
tor of mammalian Hippo signaling. NPHP4 directly inter-
acted with the kinase Lats1 and inhibited Lats1-mediated 
phosphorylation of the Yes-associated protein (YAP) and   
TAZ (transcriptional coactivator with PDZ-binding do-
main), leading to derepression of these protooncogenic 
transcriptional  regulators.  Moreover,  NPHP4  induced 
release from 14-3-3 binding and nuclear translocation of 
YAP and TAZ, promoting TEA domain (TEAD)/TAZ/YAP-
dependent transcriptional activity. Consistent with these 
data, knockdown of NPHP4 negatively affected cellular 
proliferation and TEAD/TAZ activity, essentially pheno-
copying loss of TAZ function. These data identify NPHP4 
as a negative regulator of the Hippo pathway and suggest 
that NPHP4 regulates cell proliferation through its effects 
on Hippo signaling.
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NPHP4 regulates the phosphorylation, 
localization, and activity of TAZ
Lats1-mediated phosphorylation of TAZ on Ser-89 creates a 
phosphoepitope that is rapidly engaged by 14-3-3, leading to 
inactivation and nuclear exclusion of TAZ. To directly inves-
tigate whether NPHP4 abolished Lats1-mediated cytoplasmic 
retention of TAZ, we performed further coimmunoprecipitation 
experiments. These data revealed that the presence of NPHP4 
considerably weakens the interaction of TAZ with endogenous 
14-3-3 (Fig. 2 a), likely because of the reduced phosphory-
lation of TAZ (Fig. 2 a). Interestingly, total TAZ levels were 
markedly reduced in the cytoplasmic protein lysates not con-
taining the nuclear fraction, whereas close to equal expression 
was found in whole cell lysates. Consistently, cell fractionation 
experiments showed a nuclear enrichment of TAZ in the pres-
ence of NPHP4 (Fig. 2 b). To confirm these findings by immuno-
fluorescence, we used nontransformed immortalized breast 
epithelial cells (MCF-10A; Soule et al., 1990; Debnath et al., 
2003). Exogenously expressed TAZ and YAP were localized 
predominantly in the cytoplasm, suggesting the presence of 
active Hippo signaling. Overexpression of NPHP4 shifted 
both TAZ and YAP to the nuclear compartment (Fig. 2 c), in-
dicating NPHP4-dependent Hippo inactivation and TAZ/YAP 
derepression. Collectively, these data indicate that NPHP4, 
by interacting with and inhibiting the kinase Lats1, promotes 
nuclear targeting of TAZ and YAP, resulting in enhanced TEAD-
dependent transcription.
NPHP4 exerts its effect on Hippo signaling 
through relieving Lats1-mediated inhibition 
of TAZ
Lats1 physically interacts with TAZ and phosphorylates TAZ 
at Ser-89, which is part of the 14-3-3–binding motif (Kanai   
et al., 2000; Varelas et al., 2010). The identification of NPHP4 
as a novel Lats1-interacting protein prompted us to evaluate the 
effect of NPHP4 on Lats1. We therefore coexpressed FLAG-
tagged Lats1 with GFP-tagged TAZ in the presence or absence 
of V5-tagged NPHP4. Interestingly, NPHP4 inhibited the inter-
action of Lats1 with its target protein TAZ (Fig. 3 a), suggesting 
that the inhibitory role of NPHP4 on the Lats1 kinase activ-
ity involves inhibition of target protein binding. Accordingly, 
the Lats1-induced phosphorylation of TAZ was substantially 
reduced when NPHP4 was overexpressed (Fig. 3 b). Consis-
tent with a role for NPHP4 in preventing substrate binding, 
autophosphorylation of Lats1 on Ser-909 was not affected by 
coexpression of NPHP4 (Fig. S2 a). These data implicate that 
NPHP4 does not affect the Hippo cascade upstream of Lats1. 
To examine whether NPHP4 could antagonize the repressive   
effect of Lats1 on TAZ/TEAD activity, we performed TAZ/
TEAD reporter assays and included Lats1 into the assay. As 
expected, the presence of overexpressed Lats1 reduced TAZ 
activity (Fig. 3 c). The decline in TAZ/TEAD activity to 68% 
was reversed by coexpression of NPHP4, which not only dere-
pressed the Lats1 effect but further increased TAZ/TEAD activ-
ity to 118% (Fig. 3 c). The fact that the interaction of NPHP4 
with Lats1 abrogated the interaction of the latter protein with 
TAZ suggests that Lats1 and NPHP4 compete for TAZ binding 
cystic kidney disease reminiscent of a severe human disorder 
called nephronophthisis (NPH; Hossain et al., 2007; Makita 
et al., 2008).
NPH, a genetically heterogeneous, autosomal recessive 
cystic kidney disease, is the most common genetic cause of 
end-stage renal disease in the first decades of life. Patients with 
NPH develop small-sized kidneys with multiple cysts at the re-
nal corticomedullary boarder (Hildebrandt et al., 2009). Reces-
sive mutations in 11 disease-causing genes (NPHP1–11) have 
been identified that encode for the so-called nephrocystins or 
NPH proteins (NPHPs). Just like the vast majority of proteins 
involved in cystic kidney disease, most of the NPHPs localize to 
the primary cilium (Fliegauf et al., 2007), a sensory organelle 
that is present on almost all cells of the human body and re-
quired to transmit extracellular signals to the interior of the cell 
(Berbari et al., 2009; Gerdes et al., 2009). Intriguingly, whereas 
loss of NPHPs results in kidney degeneration, several of these 
ciliary proteins, including members of the functional NPHP 
complex, have been found to be up-regulated in various tumors, 
such as breast cancer (Bowers and Boylan, 2004), pancreas 
carcinoma (Carter et al., 2010), and colorectal cancer (Sjöblom 
et al., 2006; Wood et al., 2007).
Results and discussion
NPHP4 is a novel antagonist of Hippo 
signaling that interacts with Lats1
Because small kidney size is one of the most striking clinical 
features of NPH patients, we asked whether NPHPs might regu-
late Hippo signaling. To directly test whether NPHP1 or NPHP4 
interacts with Lats1 and MST1, the two core components of the 
Hippo pathway, we immunoprecipitated FLAG-tagged NPHP1 
and NPHP4 from HEK293T cells and analyzed the precipitates 
for coprecipitating Lats1 and MST1. Interestingly, endogenous 
Lats1 coprecipitated with NPHP4 but not with NPHP1 (Fig. 1 a), 
and this coprecipitation could be confirmed vice versa (Fig. 1 b). 
MST1 neither coprecipitated with NPHP4 nor with NPHP1 
(Fig. S1 a). Next, we examined the functional consequences of 
the Lats1–NPHP4 interaction on Hippo signaling using an es-
tablished GAL4-TEAD luciferase reporter system, the repres-
sion of which reflects activity of the Hippo pathway (Lei et al., 
2008; Tian et al., 2010). As expected, exogenous TAZ or YAP 
dramatically increased GAL4-TEAD activity (Lei et al., 2008). 
Coexpression of NPHP4 with TAZ or YAP augmented TEAD4 
transcriptional activity to 156 or 138%, respectively, in compar-
ison with TAZ/YAP expression alone (Fig. 1 c). This effect of 
NPHP4 was dose dependent (Fig. S1 b). Interestingly, expres-
sion of NPHP4 without TAZ or YAP was not sufficient to induce 
TEAD activation, indicating that NPHP4 exerts its effect only if 
a certain threshold activation of TAZ/YAP is exceeded, suggest-
ing that NPHP4 might act as an antagonistic enhancer of dysreg-
ulated Hippo signaling. Not only TAZ/YAP-dependent activation 
of the reporter plasmid but also binding of TAZ to the promoter 
region of connective tissue growth factor (CTGF), a previously 
described TAZ/TEAD target gene, was significantly increased 
as shown by chromatin immunoprecipitation emphasizing the 
biological significance of our results (Fig. 1 d).635 NPHP4 negatively regulates the Hippo pathway • Habbig et al.
Figure 1.  NPHP4 interacts with Lats1 and activates TAZ/YAP/TEAD transcription. (a) HEK293T cells were transiently transfected with the FLAG-tagged 
NPHPs NPHP1 (F.NPHP1) or NPHP4. After immunoprecipitation (IP) with FLAG (M2) beads, Western blot analysis revealed that endogenous Lats1 copre-
cipitated with NPHP4 but not with NPHP1. (b) Lysates from HEK293T cells transfected with either control vector (Input 1) or FLAG-tagged NPHP4 (Input 
2 + 3) were subjected to immunoprecipitation using an anti-Lats1 (IP 1 and 2) or a control (anti-V5; IP 3) antibody. Western blot (WB) analysis showed 
that NPHP4 coprecipitated specifically with endogenous Lats1. (c) NPHP4 enhances the activity of the transcriptional coactivators TAZ and YAP. Plasmids 
encoding the indicated proteins or empty pcDNA6 vector were cotransfected in HEK293T cells together with the TEAD reporter plasmids as indicated in 
Materials and methods. Coexpression of NPHP4 increased the TAZ/YAP-dependent signaling to 156 and 138%, respectively (n = 3 for YAP and n = 5 
for TAZ; *, P < 0.05). Expression of the indicated proteins was confirmed by Western blot analysis. (d) HEK293T cells were transfected with the indicated 
constructs. The chromatin immunoprecipitation assay revealed that NPHP4 enhances the binding of TAZ to the promoter region of CTGF, a known target 
gene of TAZ. Error bars represent SEM.JCB • VOLUME 193 • NUMBER 4 • 2011   636
Figure 2.  NPHP4 regulates the localization of TAZ. (a) HEK293T cells were transfected with the indicated constructs. Immunoprecipitation of TAZ or a 
control protein (Eps) with the FLAG antibody revealed that cotransfection of NPHP4, but not of NPHP1 or empty vector, decreased the interaction of TAZ 
with endogenous 14-3-3. Equal amounts of precipitated FLAG.TAZ were confirmed by staining the precipitates with anti-FLAG. Staining for TAZ in the 
cytoplasmic lysates used for immunoprecipitation (IP) showed reduced TAZ levels in the presence of NPHP4, whereas whole cell lysates (WCL), including 
the nuclear fraction, confirmed close to equal expression of TAZ. Staining for phosphorylation of the 14-3-3–binding motif of TAZ (phospho S89) revealed 
reduced phosphorylation of TAZ in the presence of NPHP4. (b) Cell fractionation experiments of HEK293T cells expressing the indicated proteins demon-
strated that coexpression of NPHP4, but not NPHP1, increased the amount of TAZ in the nuclear compartment. Fibrillarin and 14-3-3 were used as nuclear 
and cytosolic marker proteins, respectively. (c) Breast epithelial cell MCF-10A was transfected with FLAG-tagged TAZ (F.TAZ) or FLAG-tagged YAP together 
with V5-tagged NPHP4 (V5.NPHP4) and stained with anti-FLAG and anti-V5 antibodies. In the absence of overexpressed NPHP4, F.TAZ/F.YAP showed 
a predominantly cytoplasmic localization (cells marked with arrowheads). In contrast, coexpression of V5.NPHP4 led to a highly significant increase in 
nuclear TAZ/YAP (bars, 10 µm; P < 0.01). WB, Western blot.637 NPHP4 negatively regulates the Hippo pathway • Habbig et al.
reduction of the NPHP4 effect on TAZ/TEAD activity (Fig. S2 b).   
To further confirm this finding, we generated a TAZ mutant 
(TAZ 4SA) lacking all Lats1 phosphorylation sites. Remarkably, 
the activity of this TAZ mutant in the reporter assay was not in-
fluenced by NPHP4 (Fig. 3 d). Collectively, these data indicate that 
under physiological conditions. This competitive inhibition 
might be the functional basis of the reduced Lats1-mediated 
TAZ phosphorylation that we have observed. To prove that Lats1 
mediates the effect of NPHP4, we knocked down Lats1. Even 
a moderate decline in Lats1 expression resulted in a significant   
Figure 3.  NPHP4 derepresses the inhibition 
of  TAZ  by  Lats1.  (a)  NPHP4  abrogates  the   
interaction of Lats1 and TAZ. FLAG-tagged 
Lats1 (F.Lats1) was coexpressed with GFP-tagged 
TAZ (GFP.TAZ) in the presence or absence of 
V5-tagged NPHP4 (V5.NPHP4) in HEK293T 
cells. After immunoprecipitation (IP) with FLAG 
(M2) beads, Western blot (WB) analysis re-
vealed that the interaction of Lats1 and TAZ was 
abolished in the presence of NPHP4. FLAG.
Eps served as a control protein. Both FLAG.
Lats1 and FLAG.Eps were stained in the pre-
cipitates to control the comparable efficiency 
of  the  immunoprecipitation.  (b)  Overexpres-
sion of NPHP4 reduces the phosphorylation of 
TAZ by Lats1. HEK293T cells were transfected 
with the indicated constructs. Cell lysates were 
analyzed by Western blotting using the pYAP–
Ser-127/pTAZ–Ser-89  antibody.  (c)  NPHP4 
derepresses the inhibitory effect of Lats1 on 
TAZ  signaling.  Plasmids  encoding  the  indi-
cated proteins or empty pcDNA6 vector were   
cotransfected  into  HEK293T  cells  together   
with the TEAD reporter plasmids as indicated   
in Material and methods. As expected, Lats1   
reduced  TEAD/TAZ  activity.  Additional  co-
expression  of  NPHP4  reversed  this  effect   
(n = 4; *, P < 0.05). Expression of the indicated 
proteins was confirmed by Western blotting.   
(d) The Lats1-resistant mutant of TAZ (TAZ 4SA) 
could not be activated by NPHP4, suggesting 
that NPHP4 regulates TAZ signaling through 
interference with Lats1-dependent phosphory-
lation of TAZ (n = 3). Error bars represent 
SEM. WCL, whole cell lysate.JCB • VOLUME 193 • NUMBER 4 • 2011   638
age (St John et al., 1999). Therefore, we asked whether NPHP4 
is indeed a driving force for proliferation in tumor cells. We 
therefore took advantage of the MCF-7 breast cancer cell line, 
in which small hairpin RNA–mediated knockdown of TAZ 
had been demonstrated to result in decreased cellular prolif-
eration and delayed tumorigenesis in nude mice (Chan et al., 
2008). We used RNAi to deplete TAZ and NPHP4 and exam-
ined the rate of DNA synthesis by analyzing incorporation of 
the thymidine analogue BrdU. Strikingly, just like knockdown 
of TAZ itself, loss of NPHP4 resulted in a decreased number 
NPHP4 acts as a potent negative regulator of Hippo signaling 
by modifying Lats1-dependent phosphorylation and, thereby, 
the localization of TAZ.
NPHP4 and TAZ regulate the proliferative 
potential of tumor cells
Down-regulation of Lats1 activity has been reported in vari-
ous tumor entities (Hisaoka et al., 2002; Takahashi et al., 2005;   
Jiang et al., 2006), and Lats1-deficient mice spontaneously develop 
ovarian cancer at 3 mo and soft tissue sarcoma at 4–10 mo of 
Figure 4.  TAZ and NPHP4 influence cell proliferation and TAZ/TEAD target gene expression in MCF-7 cells. (a and b) MCF-7 cells were transfected with the 
indicated siRNAs. After 72 h, the cells were serum starved for 5 h followed by BrdU labeling for 30 min in the presence of serum. BrdU-positive cells were 
detected using an anti-BrdU antibody, and nuclei were counterstained using DAPI. The reduction of TAZ or NPHP4 leads to a decrease in cell proliferation, 
and the combined knockdown had no additional effect (n = 3; *, P < 0.05 as compared with the negative control; bars, 20 µM) (c) Knockdown of TAZ or 
NPHP4 led to a decreased expression of the TAZ/TEAD downstream target CTGF. 72 h after transfection of the indicated siRNAs into MCF-7 cells, the CTGF 
expression levels were analyzed using qPCR (n = 3; *, P < 0.05; **, P < 0.01). The knockdown of NPHP4 and TAZ was validated using qPCR (Fig. S3 a).   
Error bars represent SEM. hTAZ, human TAZ; hNPHP4, human NPHP4.639 NPHP4 negatively regulates the Hippo pathway • Habbig et al.
repair. This might explain some aspects of the phenotype of 
NPH. Our data show that the expression level of NPHP4 con-
trols the activity of the Hippo mediator TAZ, suggesting that 
NPHP4 may act as a repressor of Hippo and enhancer of prolif-
erative signaling, which may be critical for kidney development 
and repair.
Second, inappropriate activation of TAZ/TEAD through 
hyperregulated NPHP4 in mature tissues may contribute to tu-
morigenesis and explain why several NPHPs are overexpressed 
in various tumors. The ubiquitous expression of NPHP4, in-
cluding in breast cancer cells, also implicates that this potential   
tumor-promoting function of NPHP4 is not restricted to the   
kidney but rather represents a general mechanism. Understand-
ing the degree to which this plays a role in carcinogenesis in vivo 
will require further studies using cancer models in laboratory an-
imals and gene expression analyses in human patient samples.
Materials and methods
Cell culture
HEK293T, A498, and MCF-7 cells were maintained in DME supplemented 
with 10% FBS. MCF-10A cells were cultured in DME/F12 supplemented 
with  5%  horse  serum,  0.5  µg/ml  hydrocortisone,  100  ng/ml  cholera 
toxin, 20 ng/ml EGF, and 10 µg/ml insulin (Debnath et al., 2003). HK2 
cells were cultured in keratinocyte serum-free medium supplemented with   
0.05 mg/ml pituitary extract and 5 ng/ml EGF.
Cell fractionation
HEK293T cells were transiently transfected with the indicated constructs   
using the calcium phosphate method. Cells were disrupted in a hypotonic 
buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 
0.05% NP-40, and protease inhibitors). After centrifugation at 3,000 g for 
10 min, the cytoplasmic fraction was taken from the supernatant. The pellet 
was washed with PBS and, after centrifugation for 10 min at 10,000 g, 
treated with a hypertonic buffer (5 mM Hepes, pH 7.9, 1.5 mM MgCl2, 
0.2 mM EDTA, 0.5 mM DTT, 26% glycerol, 300 mM NaCl, and protease 
inhibitors) to yield the nuclear fraction. Both fractions were analyzed by 
Western blotting.
Immunofluorescence
MCF-10A cells were seeded onto coverslips and transfected with the 
indicated plasmids using transfection reagent (Genejuice; EMD). 24 h 
afterward, cells were rinsed with PBS several times and fixed with 4% 
of BrdU-positive cells, and the combined knockdown of both 
TAZ and NPHP4 had no further effect, suggesting that NPHP4 
acts as an enhancer of TAZ signaling in this pathway (Fig. 4,   
a and b). In addition, we determined the TAZ/TEAD-dependent 
transcriptional activity and measured the expression of CTGF, 
a previously described TAZ/TEAD target gene (Zhang et al., 
2009a). Knocking down NPHP4, just as depletion of TAZ, re-
sulted in decreased expression of CTGF (Fig. 4 c). The effi-
ciency of the NPHP4 and TAZ knockdown in these experiments 
was validated by quantitative PCR (qPCR; Fig. S3 a). The role 
of NPHP4 as a positive regulator of cell proliferation could be 
confirmed not only in a renal cell carcinoma cell line (A498) but 
also in differentiated kidney epithelial cells (HK2). These data 
strongly suggest that NPHP4 is a critical regulator, mediating 
the proliferation of both oncogenically transformed and normal 
epithelial cells (Fig. S3, b and c).
Collectively, we found that NPHP4 is a potent activator of 
TAZ and YAP, as illustrated schematically in Fig. 5. Our data, 
for the first time, implicate an NPHP to have a proproliferative 
function and suggest that NPHP4 negatively regulates the tumor-
suppressive Hippo pathway. Our findings further provide a pos-
sible explanation for the phenotype of small-sized kidneys and 
atrophic tubular epithelium in patients carrying loss-of-function 
mutations in NPHP4. In epithelial cells, loss of NPHP4 might   
lead to insufficient TAZ-dependent proliferative signaling under 
certain conditions. This idea is supported by the observation 
that two independently generated TAZ-deficient mouse models de-
velop cystic kidneys and a phenotype that, at least partly, resem-
bles human NPH (Hossain et al., 2007; Makita et al., 2008).
Although further studies are needed to clarify the in vivo 
importance of the NPHP4-mediated control of Hippo signaling, 
our findings may have two important consequences. First, nor-
mal organ development as well as repair after damage requires 
cellular proliferation to guarantee organ growth and tissue re-
generation. Thus, lack of NPHP4 may lead to the overactivity of 
the Hippo signaling pathway, resulting in antiproliferative cel-
lular signaling and, thus, leading to reduced growth or insufficient 
Figure  5.  NPHP4  antagonizes  the  Hippo 
pathway.  Active  Hippo  signaling  leads  to 
phosphorylation  (P)  and  activation  of  the 
large tumor suppressor (LATS) kinase, which 
in turn phosphorylates YAP at Ser-127 and 
TAZ at Ser-89. This creates phosphoepitopes 
that are rapidly engaged by 14-3-3, leading 
to cytoplasmic retention of YAP and TAZ and 
the inhibition of their transcriptional activation 
potential. NPHP4 abrogates the interaction of 
large  tumor  suppressor  with  its  substrates 
YAP and TAZ, which abolishes 14-3-3 bind-
ing  and  allows  for  nuclear  translocation  of 
YAP and TAZ.JCB • VOLUME 193 • NUMBER 4 • 2011   640
5-TTGGTGAGTGTTCCTAGGCTA-3. siRNA strands were purchased from 
Biomers or QIAGEN (Lats1 #12 and Lats1 #13 siRNA). siRNAs against 
NPHP4 and TAZ have been tested by qPCR (Fig. S3 a), and the siRNA 
against TAZ has been previously described (Chan et al., 2008).
Antibodies were purchased from Sigma-Aldrich (anti-FLAG/M2, 
anti– actin, anti-WWTR1/TAZ, and antitubulin), Cell Signaling Technol-
ogy (anti-Lats1, antiphospho-Lats1 Ser-909, antiphospho-YAP Ser-127, and 
anti-MST1), AbD Serotec (anti-V5), Millipore (anti-V5), Abcam (antifibrilla-
rin), and Santa Cruz Biotechnology, Inc. (anti-GFP and anti–14-3-3).
qPCR
MCF7 cells were transfected with the indicated siRNAs (final concentration 
of 20 nM) using a transfection reagent (Oligofectamine; Invitrogen). 72 h 
after transfection, cells were harvested in lysis reagent (QIAzol; QIAGEN), 
and RNA was isolated using the phenol-chloroform method. After DNase 
treatment (Invitrogen), the reverse transcription reaction was performed 
with a High-Capacity cDNA kit (Applied Biosystems). TaqMan assays (Ap-
plied Biosystems) were used to evaluate CTGF (Hs00170014_m1) levels. 
ActB (4326315E), HPRT1 (Hs02800695), and 18SrRNA (4319413E) 
served as endogenous controls. The efficiency of the NPHP4 siRNAs was 
confirmed  using  a  TaqMan  assay  (Hs00296416_m1;  Applied  Biosys-
tems), the TAZ siRNA was validated using SYBR green qPCR (TAZ forward 
primer, 5-ACCCACCCACGATGACCCCA-3, and TAZ reverse primer,   
5-GCACCCTAACCCCAGGCCAC-3), and HPRT1 served as an endoge-
nous control (HPRT1 forward primer, 5-TGACACTGGCAAAACAATGCA-3,   
and HPRT1 reverse primer, 5-GGTCCTTTTCACCAGCAAGCT-3). All 
qPCR experiments were performed on a real-time PCR system (7900HT; 
Applied Biosystems) and repeated at least three times. Error bars shown 
in the figures represent SEM. P-values were calculated using an unpaired 
Student’s t test.
BrdU assays
MCF-7, A498, and HK2 cells were transfected with the indicated siRNAs 
(final concentration of 20 nM) using Oligofectamine and processed 72 h 
after transfection. The MCF-7 cells were serum starved for 5 h followed 
by 30-min BrdU labeling in complete growth medium. After fixation in 
100% methanol for 20 min, cells were stained with the BrdU Labeling and 
Detection Kit I (Roche). Nuclei were counterstained with DAPI. Pictures   
were randomly taken with a microscope (Axiovert 200) and the Axio-
vision software. At least 400 cells were counted for each point within each 
single experiment.
The A498 and HK2 cells were labeled with BrdU in complete growth 
medium for 3 or 12 h, respectively. Afterward, the cells were fixed with 
70% ethanol overnight after treatment with 2 N HCl/0.5% Triton X-100 and   
0.1 M sodium tetraborate. Cells were stained with a mouse anti-BrdU anti-
body (Sigma-Aldrich) and Dylight 488–conjugated anti–mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc.). DNA was counterstained with prop-
idium iodide (Sigma-Aldrich), and cells were analyzed by FACS. The 
amount of BrdU + cells for each condition was calculated in comparison to 
the scrambled siRNA–treated control cells. Error bars shown in the figure 
represent SEM. P-values were calculated using an unpaired Student’s t test.
Chromatin immunoprecipitation
HEK293T cells were transfected with the plasmids indicated in the figures 
using the calcium phosphate method. 2 × 10
7 cells were cross-linked with 
1% formaldehyde (Merck) for 10 min at RT. Cross-linking was quenched 
by cold PBS. Cells were scraped into 50 ml PBS containing protease in-
hibitors (PMSF and apotinin) and pelleted for 5 min at 300 g at 4°C. 
Cells were lysed, and the lysate was sonicated to a DNA fragment with 
a length of 1 kbp. Lysates were cleared by CL4B200 beads (Sigma-
Aldrich). Then, 2 µg anti-FLAG antibody and anti– actin as a negative 
control was added for overnight immunoprecipitation. 60 µl of preblocked 
GammaBind G Sepharose beads (GE Healthcare) was added for 1 h at 
4°C with rotation. After washing, beads were eluted in 500 µl of buffer. 
The eluate was incubated for 65°C overnight to reverse cross-linking fol-
lowed by proteinase K (Roche) digestion and DNA recovery with a PCR 
purification kit (QIAquick; QIAGEN). DNA was eluted in 50 µl H2O, and 
4 µl of the eluate was used per well as the template for real-time PCR using 
SYBR green–based master mix (Applied Biosystems). Primers for the human 
CTGF promoter region close to the TAZ response element had the following 
sequences: 5-GAGACTGCATCCTGAGTCACAC-3 (forward primer) and 
5-GGCTCTTGAAACTCTCCAAAGA-3 (reverse primer).
Online supplemental material
Fig. S1 shows that NPHP1 and NPHP4 do not interact with MST1 and 
demonstrates the dose-dependent effect of NPHP4 on TAZ signaling.   
PFA for 10 min. After blocking with 5% normal donkey serum and 0.1% 
Triton  X-100  in  Dulbecco’s  PBS,  cells  were  sequentially  stained  with 
the  indicated  antibodies  (primary  antibodies:  rabbit  anti-FLAG  [pAb] 
and mouse anti-V5 [mAb]; secondary antibodies: Cy3-conjugated anti– 
rabbit  IgG  and  Cy2-conjugated  anti–mouse  IgG  obtained  from  Jack-
son ImmunoResearch Laboratories, Inc.). Afterward, the coverslips were 
mounted  with  Prolong  gold  with  DAPI  (Invitrogen)  and  subjected  to   
immunofluorescence microscopy. Pictures were taken with a microscope 
(objectives:  Plan  Apochromat  20×/0.8  NA  differential  interference 
contrast,  EC  Plan  Neofluar  40×/1.3  NA  oil  differential  interference 
contrast, and C-Apochromat 63×/1.22 W; Axiovert 200; Carl Zeiss) 
equipped with a camera (AxioCam MRm; Carl Zeiss) and an imaging 
system (ApoTome; Carl Zeiss) using Axiovision 4.8 software for acquisi-
tion and subsequent image processing (Carl Zeiss). Figures were as-
sembled using Macromedia Freehand 11 software (Adobe). About 200 
cells were counted and quantified in regard to the localization of TAZ 
and YAP with or without NPHP4 coexpressed in the same cell. P-values 
were calculated using Fisher’s exact test.
Luciferase assays
The luciferase reporter plasmid (pGBD-Hyg-Luc) was transfected together 
with an activator plasmid (pGal4-TEAD), pGL4.74 (Promega) for normal-
ization, and the indicated expression plasmids (TAZ, YAP, NPHP4, Lats1, 
and the control empty pcDNA6) into HEK293T cells in a 96-well format 
using Lipofectamine LTX (Invitrogen) as a transfection reagent. The total 
amount of DNA was always adjusted with empty pcDNA6. Renilla lucif-
erase and firefly luciferase activities were measured by using a reporter 
assay system (Dual Luciferase; Promega) in a luminometer (Mithras LB 940; 
Berthold) 24 h after transfection. For the Lats1 siRNA experiment, the indi-
cated plasmids and siRNAs were cotransfected into HEK293T cells. The 
measurement was performed 48 h after transfection. Transfections and 
measurements were performed in triplicates for each single experiment, 
and each experiment was repeated at least three times. Error bars shown 
in the figures represent SEM. P-values were calculated using an unpaired 
Student’s t test. Equal expression of the transfected proteins was confirmed 
by Western blot analysis.
Coimmunoprecipitation
HEK293T cells were transiently transfected using the calcium phosphate 
method, and the total amount of DNA was always adjusted with empty 
pcDNA6.  The  following  day,  cells  were  harvested  with  ice-cold  PBS.   
A small aliquot of this cell suspension was taken, and the cells of which 
were lysed directly in SDS-PAGE sample buffer (whole cell lysate). The 
harvested cells were lysed in a 1% Triton X-100 buffer (1% Triton X-100, 
20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 50 mM NaF, 15 mM Na4P2O7,   
2 mM Na3VO4, and complete protease inhibitors [PIM; Roche]) for 15 min 
on ice. After centrifugation at 15,000 g for 15 min at 4°C and ultracentri-
fugation at 100,000 g for 30 min at 4°C, the supernatant was incubated 
at 4°C for 2 h with the anti-FLAG (M2) antibody covalently coupled to aga-
rose beads (Sigma-Aldrich) or with 1 µg of the appropriate first antibody 
and 20 µl protein G–Sepharose beads (GE Healthcare). Before the addi-
tion of antibodies, a small aliquot of each supernatant was preserved and 
diluted with 2× SDS-PAGE sample buffer for later Western blot analysis 
(lysate). The beads were washed extensively with lysis buffer, and bound 
proteins were resolved by SDS-PAGE, blotted on to polyvinylidene fluoride 
membranes, and visualized with enhanced chemiluminescence after incu-
bation of the blots with the respective antibodies.
Plasmids, reagents, and antibodies
TAZ, YAP, Salvador, and Lats1 cDNAs were provided by M. Yaffe (Mas-
sachusetts Institute of Technology, Boston, MA) and M. Sudol (Geisinger 
Clinic, Danville, PA). The TAZ 4SA mutant was generated using mutagen-
esis (QuickChange; Agilent Technologies) to mutate the serine residues in 
positions 66, 89, 117, and 306 to alanine. The GAL4-TEAD reporter sys-
tem (pGBD-Hyg-Luc and pGal4-TEAD) was purchased from Biomyx. NPHP4 
was cloned from a human kidney cDNA library. NPHP1 was cloned from 
a human kidney cDNA library into a modified pcDNA6 vector using stan-
dard PCR cloning techniques and has been described previously (Otto   
et al., 2003; Schermer et al., 2005). siRNAs used in knockdown experiments 
were directed against the following sequences: NPHP4 #5, 5-AAGCAAC-
GAGATGGTGCTACA-3; NPHP4 #6, 5-CAGATCTCGGGTCATCTCAAA-3;   
TAZ, 5-AGGTACTTCCTCAATCACA-3 (previously described and validated 
by immunoblotting with endogenous TAZ in MCF-7 cells; Chan et al., 
2008); scrambled/control, 5-AAATGTACTGCGCGTGGAGAC-3; Lats1 #1,   
5-GGAGTGTTACTCCTCCACC-3; Lats1 #2, 5-GGTTCTGAGAGTAAA-
ATTA-3, Lats1 #12, 5-CAGCAGCGTCTACATCGTAAA-3; and Lats1 #13, 641 NPHP4 negatively regulates the Hippo pathway • Habbig et al.
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